Summary:
- This article discusses the results of a clinical trial for Lilly's experimental Alzheimer's drug, donanemab (AZBT). The drug showed continued benefits in slowing cognitive decline over a 3-year period in people with early symptomatic Alzheimer's disease.
- The study found that patients taking donanemab experienced a slower rate of cognitive decline compared to those taking a placebo. This suggests the drug may be effective in treating the early stages of Alzheimer's disease.
- The findings are significant as there is a critical need for new treatments that can help slow the progression of Alzheimer's, a devastating neurodegenerative disorder that affects millions of people worldwide.